CB Insights
Technology Market Intelligence
Technology Market Intelligence
Carbylan Therapeutics is a clinical-stage, specialty, pharmaceutical company focused on the development and commercialization of proprietary combination therapies that address significant unmet medical needs. The company's initial focus is on the dev...Show all
Company (Acquired)
Phone: 510-933-8365
39899 Balentine Drive
Suite 200
Newark, 94560
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Carbylan Therapeutics | $107.8M | Nov 22, 2016 |
| See all 16 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|
| Company | Status | Description | Investors |
|---|---|---|---|
| Pittsburgh, Pennsylvania, United States | Alive / Active | Agentase, LLC is a technology company founded in December 1998 by Dr. Keith LeJeune and Dr. Alan Russell with experience in enzyme-polymer hybrid materials. The company's possesses patented technology in the synthesis and potential applications of enzyme containing polymers.ICx Agentase's expertise is developing applications and products that detect chemical and biological analytes. Their product development efforts to date fall within three broad categories: decontamination, detection (chemical...Show all | Login to see details |
| Richmond, California, United States | Acquired | Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Trancept's remaining product development candidate is TO-2070, a novel rapidly absorbed treatment for acute migraine incorporating dihydroergotamine (DHE) as the active drug, which Transcept has developed through the completion of preclinical safety studies but has not initiated a Phase 1 hu...Show all | Login to see details |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Modified hyaluronic acid polymer compositions and related methods | Sep 13, 2016 | May 29, 2018 | Patent |
| Rapid in-situ gel forming compositions prepared via reaction of vinyl sulfone derivatized hyaluronic acid with thiol derivatized polyethylene glycol at alkaline ph | Apr 18, 2012 | Nov 15, 2016 | Patent |
| Modified hyaluronic acid polymer compositions and related methods | Oct 30, 2015 | Sep 20, 2016 | Patent |
| Modified hyaluronic acid polymer compositions and related methods | Jul 16, 2014 | Nov 24, 2015 | Patent |
| Sterile hyaluronic acid polymer compositions and related methods | Jun 30, 2008 | Apr 21, 2015 | Patent |
